Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Ibrutinib in Relapsed/Refractory NHL
NCT02950220Phase 1Completed
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab and ibrutinib in non-Hodgkin lymphoma (NHL). Started Jan 2017; status: completed.
02
Drugs
pembrolizumabibrutinib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02950220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950220.